Skip to main content

Table 6 Changes in baseline to endpoint measures for sex hormones levels in two groups

From: Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome

Variables

Mean ± SD

Placebo(n = 28)

Mean ± SD

Ellagic acid (n = 29)

P1

FSH (ng/ml)

Baseline

6 ± 1.85

6.02 ± 1.91

0.57

End

6.01 ± 1.73

6.07 ± 1.9

0.601

P2

0.55

0.49

 

Mean Changes

0.01 ± 0.12

0.05 ± 0.01

0.68

LH (ng/ml)

Baseline

10.51 ± 2.19

10.84 ± 2.1

0.601

End

10.83 ± 2.02

9.73 ± 2.4

0.073

P2

0.58

0.076

 

Mean Changes

0.32 ± 0.17

-1.11 ± 0.3

0.079

Total Testosterone (ng/ml)

Baseline

0.6 ± 0.031

0.58 ± 0.023

0.61

End

0.59 ± 0.04

0.38 ± 0.017

0.038

P2

0.521

0.04

 

Mean Changes

-0.01 ± 0.09

-0.2 ± 0.06

0.042

Prolactin (ng/ml)

Baseline

19.08 ± 4.5

19.91 ± 4.07

0.73

End

19 ± 4.11

12.3 ± 2.39

0.025

P2

0.671

0.036

 

Mean Changes

0.32 ± 0.39

-7.61 ± 1.68

0.033

AMH (ng/ml)

Baseline

12.02 ± 3.71

11.27 ± 3.07

0.43

End

11.9 ± 3.1

7.2 ± 1.01

0.036

P2

0.318

0.04

 

Mean Changes

-0.12 ± 0.61

-4.07 ± 2.06

0.045

  1. Data are expressed as means ± SD. FSH Follicle-stimulating hormone, LH Luteinizing hormone, AMH Anti-Mullerian hormone
  2. P1: Comparison of the mean of sex hormones between the two groups of Ellagic acid and placebo (Independent samples t-test)
  3. P2: Comparison of mean of sex hormones in each group at baseline and end of study (Paired samples t-test)